Radiomic Features and Machine Learning for the Discrimination of Renal Tumor Histological Subtypes: A Pragmatic Study Using Clinical-Routine Computed Tomography.
Johannes UhligAndreas LehaLaura M DelongeAnna-Maria HaackBrian ShuchHyun S KimFelix BremmerLutz TrojanJoachim LotzAnnemarie UhligPublished in: Cancers (2020)
This study evaluates the diagnostic performance of radiomic features and machine learning algorithms for renal tumor subtype assessment in venous computed tomography (CT) studies from clinical routine. Patients undergoing surgical resection and histopathological assessment of renal tumors at a tertiary referral center between 2012 and 2019 were included. Preoperative venous-phase CTs from multiple referring imaging centers were segmented, and standardized radiomic features extracted. After preprocessing, class imbalance handling, and feature selection, machine learning algorithms were used to predict renal tumor subtypes using 10-fold cross validation, assessed as multiclass area under the curve (AUC). In total, n = 201 patients were included (73.7% male; mean age 66 ± 11 years), with n = 131 clear cell renal cell carcinomas (ccRCC), n = 29 papillary RCC, n = 11 chromophobe RCC, n = 16 oncocytomas, and n = 14 angiomyolipomas (AML). An extreme gradient boosting algorithm demonstrated the highest accuracy (multiclass area under the curve (AUC) = 0.72). The worst discrimination was evident for oncocytomas vs. AML and oncocytomas vs. chromophobe RCC (AUC = 0.55 and AUC = 0.45, respectively). In sensitivity analyses excluding oncocytomas, a random forest algorithm showed the highest accuracy, with multiclass AUC = 0.78. Radiomic feature analyses from venous-phase CT acquired in clinical practice with subsequent machine learning can discriminate renal tumor subtypes with moderate accuracy. The classification of oncocytomas seems to be the most complex with the lowest accuracy.
Keyphrases
- machine learning
- computed tomography
- artificial intelligence
- deep learning
- renal cell carcinoma
- patients undergoing
- big data
- clinical practice
- acute myeloid leukemia
- image quality
- positron emission tomography
- climate change
- dual energy
- magnetic resonance imaging
- stem cells
- primary care
- high resolution
- ejection fraction
- clear cell
- clinical trial
- randomized controlled trial
- acute lymphoblastic leukemia
- single cell
- magnetic resonance
- chronic kidney disease
- newly diagnosed
- neural network
- mass spectrometry
- mesenchymal stem cells
- case control